BioCryst Pharmaceuticals is trading at $9.76, up +4.05%, extending gains after its August 5 second-quarter results.
- Revenue reached $218.3 million, beating expectations.
- Management raised full-year 2026 total revenue guidance to $690 million–$715 million from $635 million–$660 million, primarily reflecting $55.7 million recognized from the navenibart European licensing agreement; ORLADEYO guidance was unchanged.
- No separate August 10 announcement was identified.